Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 18/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | PTGIR | P43119 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2507813 | 0.88 | PTGDR2 (0.63) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL2285931 | 0.86 | PTGDR2 (0.50) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL13521853 | 0.85 | PTGDR2 (0.53) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL2279306 | 0.84 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL2280648 | 0.82 | CYP3A4 (0.68) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL349853 | 0.82 | CYP3A4 (0.70) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL2281493 | 0.81 | PTGDR2 (0.49) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL3264240 | 0.79 | CYP3A4 (0.45) | PTGDR2TBXA2RPTGDRCYP3A4 | |
| SCHEMBL2279327 | 0.79 | CYP3A4 (0.52) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL2275833 | 0.78 | PTGDR2 (0.52) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 9/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.